Cargando…

Quantification of (11)C-PIB kinetics in cardiac amyloidosis

BACKGROUND: The purpose of this work was to determine the optimal tracer kinetic model of (11)C-PIB and to validate the use of the simplified methods retention index (RI) and standardized uptake value (SUV) for quantification of cardiac (11)C-PIB uptake in amyloidosis. METHODS AND RESULTS: Single-ti...

Descripción completa

Detalles Bibliográficos
Autores principales: Kero, Tanja, Sörensen, Jens, Antoni, Gunnar, Wilking, Helena, Carlson, Kristina, Vedin, Ola, Rosengren, Sara, Wikström, Gerhard, Lubberink, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7326793/
https://www.ncbi.nlm.nih.gov/pubmed/30039218
http://dx.doi.org/10.1007/s12350-018-1349-x
_version_ 1783552411545108480
author Kero, Tanja
Sörensen, Jens
Antoni, Gunnar
Wilking, Helena
Carlson, Kristina
Vedin, Ola
Rosengren, Sara
Wikström, Gerhard
Lubberink, Mark
author_facet Kero, Tanja
Sörensen, Jens
Antoni, Gunnar
Wilking, Helena
Carlson, Kristina
Vedin, Ola
Rosengren, Sara
Wikström, Gerhard
Lubberink, Mark
author_sort Kero, Tanja
collection PubMed
description BACKGROUND: The purpose of this work was to determine the optimal tracer kinetic model of (11)C-PIB and to validate the use of the simplified methods retention index (RI) and standardized uptake value (SUV) for quantification of cardiac (11)C-PIB uptake in amyloidosis. METHODS AND RESULTS: Single-tissue, reversible and irreversible two-tissue models were fitted to data from seven cardiac amyloidosis patients who underwent (11)C-PIB PET scans and arterial blood sampling for measurement of blood radioactivity and metabolites. The irreversible two-tissue model (2Tirr) best described cardiac (11)C-PIB uptake. RI and SUV showed high correlation with the rate of irreversible binding (K(i)) from the 2Tirr model (r(2 )=0.95 and r(2 )=0.94). Retrospective data from 10 amyloidosis patients and 5 healthy controls were analyzed using RI, SUV, as well as compartment modelling with a population-average metabolite correction. All measures were higher in amyloidosis patients than in healthy controls (p=.001), but with an overlap between groups for K(i). CONCLUSION: An irreversible two-tissue model best describes the (11)C-PIB uptake in cardiac amyloidosis. RI and SUV correlate well with K(i) from the 2Tirr model. RI and SUV discriminate better between amyloidosis patients and controls than K(i) based on population-average metabolite correction. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s12350-018-1349-x) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7326793
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-73267932020-07-07 Quantification of (11)C-PIB kinetics in cardiac amyloidosis Kero, Tanja Sörensen, Jens Antoni, Gunnar Wilking, Helena Carlson, Kristina Vedin, Ola Rosengren, Sara Wikström, Gerhard Lubberink, Mark J Nucl Cardiol Original Article BACKGROUND: The purpose of this work was to determine the optimal tracer kinetic model of (11)C-PIB and to validate the use of the simplified methods retention index (RI) and standardized uptake value (SUV) for quantification of cardiac (11)C-PIB uptake in amyloidosis. METHODS AND RESULTS: Single-tissue, reversible and irreversible two-tissue models were fitted to data from seven cardiac amyloidosis patients who underwent (11)C-PIB PET scans and arterial blood sampling for measurement of blood radioactivity and metabolites. The irreversible two-tissue model (2Tirr) best described cardiac (11)C-PIB uptake. RI and SUV showed high correlation with the rate of irreversible binding (K(i)) from the 2Tirr model (r(2 )=0.95 and r(2 )=0.94). Retrospective data from 10 amyloidosis patients and 5 healthy controls were analyzed using RI, SUV, as well as compartment modelling with a population-average metabolite correction. All measures were higher in amyloidosis patients than in healthy controls (p=.001), but with an overlap between groups for K(i). CONCLUSION: An irreversible two-tissue model best describes the (11)C-PIB uptake in cardiac amyloidosis. RI and SUV correlate well with K(i) from the 2Tirr model. RI and SUV discriminate better between amyloidosis patients and controls than K(i) based on population-average metabolite correction. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s12350-018-1349-x) contains supplementary material, which is available to authorized users. Springer International Publishing 2018-07-23 2020 /pmc/articles/PMC7326793/ /pubmed/30039218 http://dx.doi.org/10.1007/s12350-018-1349-x Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Kero, Tanja
Sörensen, Jens
Antoni, Gunnar
Wilking, Helena
Carlson, Kristina
Vedin, Ola
Rosengren, Sara
Wikström, Gerhard
Lubberink, Mark
Quantification of (11)C-PIB kinetics in cardiac amyloidosis
title Quantification of (11)C-PIB kinetics in cardiac amyloidosis
title_full Quantification of (11)C-PIB kinetics in cardiac amyloidosis
title_fullStr Quantification of (11)C-PIB kinetics in cardiac amyloidosis
title_full_unstemmed Quantification of (11)C-PIB kinetics in cardiac amyloidosis
title_short Quantification of (11)C-PIB kinetics in cardiac amyloidosis
title_sort quantification of (11)c-pib kinetics in cardiac amyloidosis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7326793/
https://www.ncbi.nlm.nih.gov/pubmed/30039218
http://dx.doi.org/10.1007/s12350-018-1349-x
work_keys_str_mv AT kerotanja quantificationof11cpibkineticsincardiacamyloidosis
AT sorensenjens quantificationof11cpibkineticsincardiacamyloidosis
AT antonigunnar quantificationof11cpibkineticsincardiacamyloidosis
AT wilkinghelena quantificationof11cpibkineticsincardiacamyloidosis
AT carlsonkristina quantificationof11cpibkineticsincardiacamyloidosis
AT vedinola quantificationof11cpibkineticsincardiacamyloidosis
AT rosengrensara quantificationof11cpibkineticsincardiacamyloidosis
AT wikstromgerhard quantificationof11cpibkineticsincardiacamyloidosis
AT lubberinkmark quantificationof11cpibkineticsincardiacamyloidosis